Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS.
Colombia
Spain
cancer
prevalence
reliability
symptom
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
17
02
2022
revised:
19
03
2022
accepted:
21
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was "lack of energy" (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were "problems with sexual interest or activity" (38.4%) and "dry mouth" (13.7%), respectively, and both samples agreed on the most distressing symptom: "hair loss" (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life.
Identifiants
pubmed: 35406396
pii: cancers14071624
doi: 10.3390/cancers14071624
pmc: PMC8996859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Epidemiol Rev. 2017 Jan 1;39(1):161-169
pubmed: 28472440
Breast Cancer Res Treat. 2021 Feb;186(1):15-24
pubmed: 33611666
Scand J Public Health. 2018 Feb;46(1):27-36
pubmed: 28669281
J Pain Symptom Manage. 2009 Jan;37(1):44-57
pubmed: 18538976
Colomb Med (Cali). 2018 Mar 30;49(1):128-134
pubmed: 29983473
Colomb Med (Cali). 2018 Mar 30;49(1):42-54
pubmed: 29983463
Colomb Med (Cali). 2018 Mar 30;49(1):121-127
pubmed: 29983472
J Pain Symptom Manage. 2015 Apr;49(4):790-5
pubmed: 25261638
Cancer. 2017 Apr 15;123(8):1313-1323
pubmed: 28182258
Colomb Med (Cali). 2018 Mar 30;49(1):23-34
pubmed: 29983461
Eur J Cancer. 2009 Mar;45(5):747-55
pubmed: 19117750
Colomb Med (Cali). 2018 Mar 30;49(1):9-12
pubmed: 29983459
Colomb Med (Cali). 2018 Mar 30;49(1):35-41
pubmed: 29983462
J Pain Symptom Manage. 2018 Dec;56(6):920-927
pubmed: 30176284
J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9
pubmed: 27112310
Int J Cancer. 2020 Dec 1;147(11):3029-3036
pubmed: 32449164
Colomb Med (Cali). 2018 Mar 30;49(1):13-15
pubmed: 30104803
J Pain Symptom Manage. 2016 Dec;52(6):884-891
pubmed: 27693903
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Lancet. 2015 Dec 5;386(10010):2287-323
pubmed: 26364544
Eur J Cancer. 1994;30A(9):1326-36
pubmed: 7999421
Int J Environ Res Public Health. 2020 Sep 23;17(19):
pubmed: 32977386
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Affect Disord. 2012 Dec 10;141(2-3):343-51
pubmed: 22727334
Colomb Med (Cali). 2018 Mar 30;49(1):55-62
pubmed: 29983464
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Einstein (Sao Paulo). 2017 Apr-Jun;15(2):148-154
pubmed: 28767911
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Cancer. 2000 Sep 1;89(5):1162-71
pubmed: 10964347
J Pain Symptom Manage. 2015 Oct;50(4):559-65
pubmed: 25242019
Br J Cancer. 1990 Dec;62(6):1034-8
pubmed: 2257209
Cancer Invest. 2004;22(4):526-36
pubmed: 15565810
Asian Pac J Cancer Prev. 2011;12(12):3389-96
pubmed: 22471486
Radiol Technol. 2015 May-Jun;86(5):535M-558M; quiz 559-62
pubmed: 25995413
Colomb Med (Cali). 2018 Mar 30;49(1):102-108
pubmed: 29983470
J Glob Oncol. 2018 Sep;4:1-7
pubmed: 30241220